Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on June 10, 2021. The report details the results of the Company's 2021 annual meeting of stockholders held on the same date. Six proposals were presented to and voted upon by the stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Stockholders approved significant amendments to the Company's Restated Certificate of Incorporation and elected new directors. The specific voting outcomes were as follows:
- Proposal 1 (Declassify Board): Approved with 75,290,361 votes For, 37,883 Against, and 19,058 Abstentions.
- Proposal 2 (Eliminate Supermajority Voting): Approved with 75,246,231 votes For, 86,747 Against, and 14,324 Abstentions.
- Proposal 3 (Election of Directors): All four Class III nominees were elected.
- Craig Barbarosh: 72,853,456 For, 2,451,351 Against.
- Kim Keck: 75,058,977 For, 248,186 Against.
- Cheryl Scott: 73,916,444 For, 1,390,919 Against.
- Frank Williams: 73,236,549 For, 2,071,814 Against.
- Proposal 4 (Ratify Auditor): Deloitte & Touche LLP was ratified with 77,895,304 votes For, 988,645 Against, and 10,471 Abstentions.
- Proposal 5 (Executive Compensation): Advisory approval granted with 74,996,027 votes For, 273,423 Against, and 77,852 Abstentions.
- Proposal 6 (Incentive Compensation Plan): Approved with 71,044,310 votes For, 4,235,514 Against, and 67,478 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to report the completion of the annual meeting and the associated voting tallies.
Key Facts for Investor Verification
- Verify the implementation of the board declassification and the removal of supermajority voting requirements as approved in Proposals 1 and 2.
- Confirm the terms of the newly elected Class III directors (Craig Barbarosh, Kim Keck, Cheryl Scott, Frank Williams) expire at the 2022 annual meeting.
- Review the definitive proxy statement (Schedule 14A) filed on April 30, 2021, for detailed descriptions of the proposals and the Amended and Restated 2015 Omnibus Incentive Compensation Plan.
- Note that the filing includes the Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation as Exhibit 3.1.